يعرض 1 - 10 نتائج من 14 نتيجة بحث عن '"Françoise Boyer perrard"', وقت الاستعلام: 0.89s تنقيح النتائج
  1. 1
    Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

    المؤلفون: Laurence Legros, Françoise Boyer perrard, Dana Ranta, Lydia Roy, Mario Ojeda-Uribe, Stephane Giraudier, Nathalie Parquet, Jean Christophe Ianotto, Mathieu Wemeau, Isabelle Plantier, Franck E. Nicolini, Eric Lippert, Pascale Cony-Makhoul, Fiorenza Barraco, Laure Stalnikiewicz, Frederic Garban, Brigitte Dupriez, Francois Girodon, Anne Brignier, Yazid Arkam, Mathieu Meunier, Chloe James, Valérie Rolland-Neyret, Valerie Ugo, Pierre Morel, Marie C Bene, Jean-Jacques Kiladjian

    المصدر: Blood. 140:6847-6849

    مصطلحات موضوعية: Immunology, Cell Biology, Hematology, Biochemistry

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::faca968149e403058a58c73c380fbc40
    https://doi.org/10.1182/blood-2022-156632

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis

    المؤلفون: Alessandro M. Vannucchi, Peter A. W. te Boekhorst, Claire N. Harrison, Guangsheng He, Marianna Caramella, Dietger Niederwieser, Françoise Boyer-Perrard, Minghui Duan, Nathalie Francillard, Betty Molloy, Monika Wroclawska, Heinz Gisslinger

    المصدر: Haematologica, Vol 104, Iss 5 (2019)

    مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

    وصف الملف: electronic resource

    Relation: https://haematologica.org/article/view/8897; https://doaj.org/toc/0390-6078; https://doaj.org/toc/1592-8721

    URL الوصول: https://doaj.org/article/dcdd30fc08a34d069d9bc9af3fd3e65b

    Full Text Finder
    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study

    المؤلفون: Jean-Christophe Ianotto, Aurélie Chauveau, Françoise Boyer-Perrard, Emmanuel Gyan, Kamel Laribi, Pascale Cony-Makhoul, Jean-Loup Demory, Benoit de Renzis, Christine Dosquet, Jerome Rey, Lydia Roy, Brigitte Dupriez, Laurent Knoops, Laurence Legros, Mohamed Malou, Pascal Hutin, Dana Ranta, Omar Benbrahim, Valérie Ugo, Eric Lippert, Jean-Jacques Kiladjian

    المصدر: Haematologica, Vol 103, Iss 3 (2018)

    مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

    وصف الملف: electronic resource

    Relation: https://haematologica.org/article/view/8381; https://doaj.org/toc/0390-6078; https://doaj.org/toc/1592-8721

    URL الوصول: https://doaj.org/article/0d5a03dc33044ea0b063692cf18978a6

    Full Text Finder
    أضف إلى المفضلة
  4. 4
    Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)

    المؤلفون: Jean-Jacques Kiladjian, Jean-Christophe Ianotto, Juliette Soret, Nabih Maslah, Cendrine Chaffaut, Françoise Boyer perrard, Fiorenza Barraco, Viviane Dubruille, Claude Capron, Amandine Tisserand, Valérie Rolland-Neyret, Zineb Ghrieb, Sylvie Chevret, Isabelle Plo, Marie-Hélène Schlageter, Veronique Meignin, Matthieu Resche-Rigon, Bruno Cassinat

    المصدر: Blood. 140:577-578

    مصطلحات موضوعية: Immunology, Cell Biology, Hematology, Biochemistry

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::adf57cc985ec01eca34b9429987fcb38
    https://doi.org/10.1182/blood-2022-156389

    أضف إلى المفضلة
  5. 5
    Prospective Follow-up of Patients with Myelofibrosis (MF) and Treated with Ruxolitinib in France: The Rumycup Study

    المؤلفون: Jean-Jacques Kiladjian, Françoise Boyer perrard, Kamel Laribi, Jean-Christophe Ianotto, Dana Ranta, Omar Benbrahim, Serge Bologna, Pascale Cony-Makhoul, Alberto Santagostino, Hacene Zerazhi, Abla Slimani, Olivier Fitoussi, Gabriel Etienne

    المصدر: Blood. 140:3968-3969

    مصطلحات موضوعية: Immunology, Cell Biology, Hematology, Biochemistry

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::9082da1a604edbcc1c31b06fd54976d7
    https://doi.org/10.1182/blood-2022-156628

    أضف إلى المفضلة
  6. 6
    Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

    المؤلفون: Yannick LE Bris, Jean Galtier, Dina Naguib, Mathieu Wemeau, Jean Claude Chomel, Laurence Legros, Yan Beauverd, Lise Willems, Guillaume Denis, Françoise Boyer perrard, Damien Luque-Paz, Kamel Laribi, Mélanie Mercier, Pascale Cony-Makhoul, Olivier Herault, Lydia Roy, Pierre Sujobert, Lenaig Le Clech, Sylvie Tondeur, Gaelle Laboure, Jerome Rey, Guillou Sophie, Cedric Pastoret, Pascaline Etancelin, Suzanne Tavitian, Charles Bescond, Francois Girodon, Shanti Amé, Viviane Dubruille, Eric Lippert, Chloe James, Barbara Burroni, Marc Fouassier, Marie C Béné, Jean Christophe Ianotto

    المصدر: Blood. 140:9668-9669

    مصطلحات موضوعية: Immunology, Cell Biology, Hematology, Biochemistry

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::88edf5f469c6ee74c367d89308834f4e
    https://doi.org/10.1182/blood-2022-159928

    أضف إلى المفضلة
  7. 7
    Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study

    المؤلفون: Mu Cheng, Mei Sheng Duh, Carole Paley, Chi Gao, Eyck von der Heyde, Claire N. Harrison, Mike Zuurman, Timothy Devos, Wendy Y. Cheng, Melody Wu, Clemens Schulte, Francesco Passamonti, Françoise Boyer-Perrard, Geralyn Gilotti, Steffen Koschmieder, Lambert Busque

    المصدر: Blood. 138:3646-3646

    مصطلحات موضوعية: Ruxolitinib, Pediatrics, medicine.medical_specialty, business.industry, Immunology, Cell Biology, Hematology, medicine.disease, Biochemistry, First line therapy, Polycythemia vera, Chart review, medicine, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::02185979a64a78b48ee68fa55c6853f3
    https://doi.org/10.1182/blood-2021-148254

    أضف إلى المفضلة
  8. 8
    The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 109/L to < 100 × 109/L) at Baseline

    المؤلفون: Peter A. W. te Boekhorst, Kevin Majidi, Françoise Boyer-Perrard, Fiorenza Barraco, Heinz Gisslinger, Monika Wroclawska, Guangsheng He, Anna Marina Liberati, Minghui Duan, Ling Pan, Pantelia Roussou, Jean-Jacques Kiladjian, Dietger Niederwieser, Srdan Verstovsek, Alessandro M. Vannucchi, Paola Guglielmelli, Haitao Meng, Claire N. Harrison

    المصدر: Blood. 136:4-5

    مصطلحات موضوعية: Ruxolitinib, medicine.medical_specialty, business.industry, Immunology, Cell Biology, Hematology, medicine.disease, Biochemistry, Gastroenterology, Dose finding, Internal medicine, medicine, In patient, Platelet, Open label, Myelofibrosis, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::5dc952aa7c74c78424ee55f45f126286
    https://doi.org/10.1182/blood-2020-137742

    أضف إلى المفضلة
  9. 9
    EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis

    المؤلفون: Minghui Duan, Claire N. Harrison, Peter A. W. te Boekhorst, Françoise Boyer-Perrard, Marianna Caramella, Guangsheng He, Alessandro M. Vannucchi, Nathalie Francillard, Betty Molloy, Heinz Gisslinger, Dietger Niederwieser, Monika Wroclawska

    المساهمون: Hematology

    المصدر: Haematologica
    Haematologica, 104(5), 947-954. Ferrata Storti Foundation

    مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Ruxolitinib, Adolescent, Maximum Tolerated Dose, Gastroenterology, Drug Administration Schedule, Article, Young Adult, EXPAND, dose-finding study of ruxolitinib, myelofibrosis, low platelet, Internal medicine, Nitriles, medicine, Humans, Myelofibrosis, Adverse effect, Protein Kinase Inhibitors, Aged, Aged, 80 and over, integumentary system, business.industry, Hematology, Middle Aged, Prognosis, medicine.disease, Discontinuation, Pyrimidines, Tolerability, Primary Myelofibrosis, Toxicity, Cohort, Pyrazoles, Female, Myeloproliferative Neoplasms, business, Follow-Up Studies, medicine.drug, Stratum

    وصف الملف: application/pdf

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ace733582e7c04d6a2d423c940bfe475
    http://hdl.handle.net/2158/1176888

    أضف إلى المفضلة
  10. 10
    Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study

    المؤلفون: Laurence Legros, Laurent Knoops, Mohamed Malou, Dana Ranta, Eric Lippert, Kamel Laribi, Lydia Roy, Benoit de Renzis, Valérie Ugo, Christine Dosquet, Omar Benbrahim, Pascale Cony-Makhoul, Françoise Boyer-Perrard, Aurélie Chauveau, Emmanuel Gyan, Jean-Christophe Ianotto, Pascal Hutin, Brigitte Dupriez, Jean-Loup Demory, Jerome Rey, Jean-Jacques Kiladjian

    المساهمون: UCL - SSS/DDUV/GECE - Génétique cellulaire, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Unité de soins continus

    المصدر: Haematologica : the hematology journal, Vol. 103, no.3, p. 438-446 (2018)
    Haematologica

    مصطلحات موضوعية: Adult, Male, Oncology, medicine.medical_specialty, DNA Mutational Analysis, Age at diagnosis, Risk Assessment, Article, Polyethylene Glycols, 03 medical and health sciences, 0302 clinical medicine, Pegylated interferon, Internal medicine, Humans, Medicine, In patient, Myelofibrosis, Myeloproliferative neoplasm, Aged, Aged, 80 and over, Myeloproliferative Disorders, business.industry, Interferon-alpha, Hematology, Middle Aged, Prognosis, medicine.disease, Survival Analysis, Recombinant Proteins, 3. Good health, Primary Myelofibrosis, International Prognostic Scoring System, 030220 oncology & carcinogenesis, Cohort, Female, Myeloproliferative Neoplasms, business, Median survival, Follow-Up Studies, 030215 immunology, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::681f48176623faa876c129f164d7f71c
    https://hdl.handle.net/2078.1/213025

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء